Semeia

What Semeia does

Semeia (legal entity SÊMEIA, SAS, RCS Paris 821 556 099) is a French digital health company founded in 2017 in Toulouse by Pierre Hornus, Daniel Szeftel, and Mathieu Godart, with current headquarters at 174 quai de Jemmapes, Paris. The company develops MedicWise, a CE-marked Class IIa digital medical device platform for remote patient monitoring (télésurveillance) of chronic disease patients. Built on the underlying Wise software environment with separate Healthcare Professional and Patient spaces, MedicWise automatically collects and centralizes outpatient data — biology results from city labs, physiological parameters, patient-reported outcomes, passive data, and disease activity scores — and generates hierarchical, patient-profiled alerts against structured care pathways. The platform is delivered through six verticalized sub-brands: NephroWise (the market leader in nephrology remote monitoring for 7+ years with 15,000+ patients), CardioWise (cardiology/heart transplant), PneumoWise (pulmonology/lung transplant), HepatoWise (liver transplant), DigestWise (IBD), MentalWise (bipolar/depression), plus DiabetoWise in pilot phase with Boehringer Ingelheim. Proprietary AI components include the DynPG prognostic score (developed with INSERM UMR 1246 SPHERE and CHU Nantes) and DataLab predictive models, with 15+ clinical research partnerships across AP-HP, CHU de Bordeaux, CHU de Nantes, and Fondation FondaMental.

The business model operates primarily through institutional subscriptions and licensing to French hospitals, clinics, and care teams, with distribution entirely within France under the national ETAPES/Assurance Maladie reimbursement framework that pays physicians €28/month per ALD-covered patient. As of 2026, Semeia monitors 35,000+ patients across 500+ care structures, has achieved stated profitability with a ~70-person team, and operates with high regulatory complexity — including CE IIa MDR certification, ANS provisional certification, HDS data hosting, Référentiel Identité/INSi homologation, and RGPD/PGSSI-S compliance. Revenue is supplemented by clinical research partnerships with pharmaceutical and academic partners (Boehringer Ingelheim, GETAID, CHU consortia). The company has pursued an active M&A strategy, acquiring Optim'Care in 2022 and Healabs in 2025 (with a March 2026 merger announcement), and closed a €21M funding round in May 2026 led by Acton Capital, Mutuelles Impact, and Citizen Capital.

Name

Semeia

Legal name

SÊMEIA

Website

https://semeia.io

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Semeia is a French healthtech company that develops MedicWise, a CE-marked Class IIa remote patient monitoring platform for chronic diseases, deployed across nephrology, cardiology, mental health, pulmonology, and hepatology via six specialized sub-brands serving 500+ care teams and 35,000+ patients in France under national health-insurance reimbursement.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring Software

NAICS

Home Health Care Services (62161)

SIC

Services-Health Services (8000)

akta.pro primary industry

Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Nephrology Telemedicine Platforms (HLALAGAI), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)

Keywords

• Remote patient monitoring
• Chronic disease management
• Digital health platform
• Telemedicine software
• Medical device software

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare Institution Subscriptions: Revenue generated from healthcare institutions using MedicWise platform. The French national health insurance (Assurance Maladie) provides a 100% coverage for patients with ALD (Affection Longue Durée) and pays €28/month/patient to physicians for remote monitoring services. Semeia operates as the solution provider receiving compensation through this framework.
2. Enterprise Licensing: Licensing of specialized solutions (NephroWise, CardioWise, PneumoWise, DigestWise, MentalWise, HepatoWise) to healthcare institutions with pricing based on scale and pathology coverage.
3. Clinical Research Partnerships: Revenue from pharmaceutical partnerships for clinical studies, such as the Boehringer Ingelheim partnership for DiabetoWise pilot program involving 500 patients and 70 general practitioners.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Semeia develops and sells MedicWise, a CE-marked Class IIa digital medical device platform for remote patient monitoring of chronic diseases. The platform automatically collects, structures, and analyzes patient health data (lab results, physiological parameters, patient-reported outcomes, passive data, and disease activity scores) and is delivered through disease-specific solutions: NephroWise (nephrology), CardioWise (cardiology), PneumoWise (pulmonology), HepatoWise (hepatology), DigestWise (gastroenterology), MentalWise (mental health), and DiabetoWise (diabetes, in pilot). The solution is sold via subscriptions and licenses to hospitals, clinics, and healthcare institutions in France, with reimbursement routed through Assurance Maladie.

Product overview

Semeia operates as a multi-pathology remote patient monitoring platform centered on MedicWise, a CE IIa marked digital medical device. The portfolio includes six disease-specific solutions: NephroWise (nephrology), CardioWise (cardiology), PneumoWise (pulmonology), HepatoWise (hepatology), DigestWise (gastroenterology), and MentalWise (mental health), plus DiabetoWise in pilot phase. All solutions run on the Wise platform enabling coordinated follow-up for patients with multiple chronic conditions. The company has pursued external growth through acquisitions of Optim'Care (2022) and Healabs (2025).

Differentiator

Problem solved

Functional benefit

Brands

• MedicWise: Digital medical device for remote patient monitoring (télésurveillance). CE IIa marked medical device that collects, structures and automatically analyzes health data of chronic patients.
• NephroWise
• HepatoWise
• CardioWise
• MentalWise
• PneumoWise
• DigestWise
• DiabetoWise

Products and services

• MedicWise CE IIa marked digital medical device platform for remote patient monitoring of chronic disease patients. Automatically collects, structures, and analyzes health data including lab results, physiological parameters, patient-reported outcomes, passive data, and disease activity scores, and provides hierarchical personalized alerts and structured care pathways. Sold to hospitals, clinics, and healthcare institutions in France.
• NephroWise Specialized remote monitoring solution for chronic kidney disease, dialysis, and kidney transplant patients. Automatically centralizes biological tests, blood pressure, weight, and patient-reported data, with personalized alerts and structured care pathways; ANS-provisionally certified and reimbursed by Assurance Maladie.
• CardioWise Remote monitoring solution for heart transplant and heart failure patients. Automatically collects blood pressure, weight, heart rate, and outpatient exam results, with alerts for early detection of cardiac deterioration. Certified by the Digital Health Agency and covered by Health Insurance.
• PneumoWise Remote monitoring solution for lung transplant patients. Automatically captures FEV1, biological analyses, blood pressure, weight, and outpatient medication dispensing data. Demonstrated 80.5% patient engagement in the Wis-Up study and 60% decrease in rehospitalizations for infections.
• HepatoWise Remote monitoring solution for liver transplant patients. Real-time tracking through automatic collection of outpatient data including biology, medication dispensing, and blood pressure, centralizing liver function tests for early detection of deterioration.
• DigestWise Remote monitoring solution for chronic inflammatory bowel diseases (IBD), Crohn's disease, and ulcerative colitis. Monitors patient-reported symptoms via validated questionnaires such as IBD-Disk and centralizes biological tests and imaging for early flare-up detection.
• MentalWise Remote monitoring solution for bipolar disorders and depression. Combines physiological data (blood pressure, weight, sleep, physical activity), patient-reported outcomes (mood, anxiety, energy, irritability), and passive smartphone data, with the Article 51 Passport BP experiment showing a 42% reduction in full psychiatric hospitalizations.
• DiabetoWise Remote monitoring platform for type 2 diabetes management, currently in pilot phase with Boehringer Ingelheim. Includes AI-supported algorithms for clinical data analysis and medical decision support, with treatment recommendations aligned to SFED guidelines.
• Wise Platform Underlying software platform that powers all Semeia solutions. Provides a Shared Space for healthcare professionals and a Patient Space for teleconsultation, messaging, and interoperability services with hospital information systems.

Quantifiable outcome

• 26% reduction in patient hospitalizations in nephrology with NephroWise
• +7 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability7 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• HealabscoreStrategic or Co-development Partner · 1 March 2025Acquisition in 2025 to strengthen Semeia's expertise and consolidate market position in remote patient monitoring, particularly in nephrology.
• ChiesiminorStrategic or Co-development Partner · 1 January 2025Partnership to create educational video content about living kidney donor transplantation, integrated into NephroWise solution for donor and recipient follow-up.
• EudokiacoreStrategic or Co-development Partner · 1 June 2024Joint venture created by Semeia, Banque des Territoires, and Health for People (H4P) to address healthcare access challenges and support medical assistants in administrative tasks, freeing up physician time.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 June 2023Pharmaceutical partnership for DiabetoWise pilot project aimed at improving type 2 diabetes management. The one-year pilot study involves 500 patients recruited from 70 general practitioners across France, with treatment recommendations based on SFED (Société Francophone de Diabète) guidelines.
• Optim'CarecoreStrategic or Co-development Partner · 1 January 2022Acquisition completed in 2022 to strengthen Semeia's expertise and expand remote monitoring capabilities.
• GETAIDminorStrategic or Co-development PartnerSupporting the SECURITY clinical study for DigestWise in inflammatory bowel diseases.
• INSERM UMR 1246 SPHEREcoreStrategic or Co-development PartnerResearch collaboration for DynPG score development involving biostatisticians, epidemiologists, nephrologists and nurses spanning over two decades.
• CHU de NantescoreStrategic or Co-development PartnerClinical research partner for DynPG score and kidney transplant studies including Pr Magali Giral and Sandra Gaboriau.
• CHU de BordeauxcoreStrategic or Co-development PartnerIMPAKT project partner for immunosuppressant adherence study in kidney transplant patients, led by Pr Lionel Couki.
• Assistance Publique - Hôpitaux de Paris (AP-HP)coreStrategic or Co-development PartnerProKidney clinical study promoter, initiated by Pr Marie Essig at Hôpital Ambroise-Paré, for CKD prevention strategy.
• RenaloominorStrategic or Co-development PartnerPatient association expert in chronic kidney disease, part of ProKidney consortium for prevention strategy development.
• CNGE (Collège National des Généralistes Enseignants)minorStrategic or Co-development PartnerPart of ProKidney consortium for integrating remote monitoring into primary care.
• Fondation FondaMentalcoreStrategic or Co-development PartnerClinical partnership for bipolar patient monitoring study showing 50% reduction in suicide attempts, 41% reduction in emergency hospitalizations.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Implicity: Paris-based AI-driven remote cardiac monitoring platform for pacemaker, ICD, and heart-failure patients. Directly competes with Semeia's CardioWise in the French cardiology RPM market and shares the same enterprise sales motion to hospitals.
• Bioserenity: French connected-health company providing wearable-based remote monitoring for neurology, cardiology, and sleep. Competes with Semeia across multiple Semeia verticals (particularly cardiology and sleep-apnea-adjacent use cases) with a similar hospital-channel GTM.
• Cureety: French digital health company operating in the same French remote-monitoring reimbursement framework as Semeia. Publicly identified as a strategic partner working to structure the French RPM market — directly comparable multi-pathology platform targeting hospitals.
• Withings: French connected-health device maker whose BPM Core, Body Comp, and sleep mat generate the kind of physiological parameters Semeia ingests. Withings is a French-headquartered RPM-adjacent competitor pursuing the same hospital and chronic-care channels.
• Vivify Health: US-based RPM platform providing multi-pathology remote monitoring with mobile kits and care-pathway tools — a close functional analogue to MedicWise/NephroWise in chronic care management, with similar hospital-system enterprise sales motion.
• Vivante Health: US digital GI health company addressing Crohn's disease and ulcerative colitis with remote monitoring and patient-reported outcomes — directly comparable to Semeia's DigestWise vertical on product and target patient population.

Broad incumbents

• Omada Health: US digital chronic-disease prevention and management company covering diabetes, hypertension, and behavioral health. While not a direct French competitor, it represents the broader at-scale chronic-care RPM category Semeia is positioning MedicWise within.
• Hinge Health: Largest US digital MSK and chronic-pain care provider. Comparable business model (employer/payer + provider-channel digital therapeutics with quantified outcomes) and serves as a benchmark for valuation and category maturity for RPM-adjacent platforms.
• Doctolib: Dominant French telehealth and practice-management platform. While currently focused on teleconsultation booking, Doctolib's installed base of French physicians and hospitals is the most credible channel threat to Semeia's enterprise RPM GTM if it expands into RPM.

Emerging players

• Tilak Healthcare: Paris-based digital therapeutics company developing clinically-validated mobile games for chronic ophthalmology conditions. Comparable as a French digital-health champion pursuing CE-marked prescription digital therapeutics reimbursed by French health authorities — the same regulatory and reimbursement playbook Semeia uses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/semeia
• Xx.com/Semeia_io

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Semeia